Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2006 2
2007 4
2008 1
2009 3
2010 1
2012 6
2013 2
2014 2
2017 1
2018 3
2020 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, Hohmann EL, Wang EEL, Oneto C, Cohen SH, Berenson CS, Korman L, Lee C, Lashner B, Kraft CS, Ramesh M, Silverman M, Pardi DS, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L; ECOSPOR IV Investigators. Sims MD, et al. JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/jamanetworkopen.2022.55758. JAMA Netw Open. 2023. PMID: 36780159 Free PMC article. Clinical Trial.
Ral signaling pathway in health and cancer.
Moghadam AR, Patrad E, Tafsiri E, Peng W, Fangman B, Pluard TJ, Accurso A, Salacz M, Shah K, Ricke B, Bi D, Kimura K, Graves L, Najad MK, Dolatkhah R, Sanaat Z, Yazdi M, Tavakolinia N, Mazani M, Amani M, Ghavami S, Gartell R, Reilly C, Naima Z, Esfandyari T, Farassati F. Moghadam AR, et al. Among authors: esfandyari t. Cancer Med. 2017 Dec;6(12):2998-3013. doi: 10.1002/cam4.1105. Epub 2017 Oct 18. Cancer Med. 2017. PMID: 29047224 Free PMC article. Review.
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group. Sands BE, et al. N Engl J Med. 2024 Sep 26;391(12):1119-1129. doi: 10.1056/NEJMoa2314076. N Engl J Med. 2024. PMID: 39321363 Clinical Trial.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS; ECOSPOR III and ECOSPOR IV investigators. Kraft CS, et al. Infect Dis Ther. 2024 Oct;13(10):2105-2121. doi: 10.1007/s40121-024-01007-z. Epub 2024 Jun 28. Infect Dis Ther. 2024. PMID: 38941068 Free PMC article.
Cancer stem cells, the ultimate targets in cancer therapy.
Shabbir A, Esfandyari T, Farassati F. Shabbir A, et al. Among authors: esfandyari t. Onco Targets Ther. 2018 Jan 3;11:183-184. doi: 10.2147/OTT.S154431. eCollection 2018. Onco Targets Ther. 2018. PMID: 29379299 Free PMC article. No abstract available.
Pro-oncogenic cell signaling machinery as a target for oncolytic viruses.
Borrego-Diaz E, Mathew R, Hawkinson D, Esfandyari T, Liu Z, Lee PW, Farassati F. Borrego-Diaz E, et al. Among authors: esfandyari t. Curr Pharm Biotechnol. 2012 Jul;13(9):1742-9. doi: 10.2174/138920112800958788. Curr Pharm Biotechnol. 2012. PMID: 21740363 Review.
A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis.
Abell TL, Kuo B, Esfandyari T, Pfeifer ND, Grimaldi M, Renzulli C, Tacchi R, Zhou K, Barnes CN, Nguyen DD, Nguyen L, Talley NJ, McCallum R. Abell TL, et al. Among authors: esfandyari t. Neurogastroenterol Motil. 2023 Apr;35(4):e14523. doi: 10.1111/nmo.14523. Epub 2023 Jan 9. Neurogastroenterol Motil. 2023. PMID: 36624727 Clinical Trial.
RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).
Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, Peng W, Rouyanian A, Asvadi Kermani A, Soleimani M, Patrad E, Lialyte K, Wang K, Williamson S, Abdulkarim B, Olyaee M, Farassati F. Ezzeldin M, et al. Among authors: esfandyari t. Mol Oncol. 2014 Jul;8(5):1043-53. doi: 10.1016/j.molonc.2014.03.020. Epub 2014 Apr 13. Mol Oncol. 2014. PMID: 24785097 Free PMC article.
Ral overactivation in malignant peripheral nerve sheath tumors.
Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, Babovick-Vuksanovic D, Woo RA, Mautner VF, Kluwe L, Clapp DW, De Vries GH, Thomas SL, Kurtz A, Parada LF, Farassati F. Bodempudi V, et al. Among authors: esfandyari t. Mol Cell Biol. 2009 Jul;29(14):3964-74. doi: 10.1128/MCB.01153-08. Epub 2009 May 4. Mol Cell Biol. 2009. PMID: 19414599 Free PMC article.
31 results